Cognitive Decline and Diabetes in the Clinical Setting

Overview

Journal Med Pharm Rep

Specialty General Medicine

Date 2025 Feb 14

PMID 39949917

Authors

Boglarka Varga

Mariana Cornelia Tilinca

Laszlo Marton

Cristian-Norbert Ionescu

Monica Iudita Maria Szabo

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of our study was to evaluate the prevalence of cognitive decline in patients with diabetes in the clinical setting and to identify patient characteristics directly associated with this condition.

Methods: In our cross-sectional study, we applied the Mini Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) to determine cognitive function in 172 diabetic patients, in the clinical setting. We included 120 patients with type 2 diabetes (T2DM), 42 cases with type 1 diabetes (T1DM) and 10 patients with confirmed secondary diabetes (SDM). The mean age of the participants was 62.4 years (±1.01, min: 26 years, Max: 87 years), with median diabetes duration of 15±11.8 years.

Results: More than half (55.23%) of the subjects presented cognitive deterioration, which was diabetes type-specific (p<0.05). Mild forms affected mostly T1DM and SDM cases (31.5% and 30% vs. T2DM: 14.5%, p=0.00), whereas moderate cognitive decline was more predominant in T2DM (21.9% vs. T1DM: 7.1%, p=0.1). A higher prevalence of severe cognitive impairment was present in T1DM (14.5% vs. T2DM: 8.7%, p=0.1).The middle-aged category (40-64 years) was characterized by a more significant reduction of cognitive function in comparison with other age groups (p=0.02).No gender-related difference in the prevalence of cognitive decline was found (female: 45.83% vs male: 45.71%, p=0.98), although severe forms were significantly more suggestive for men (15.27% vs. 4.18%, p=0.04).Diabetic ketoacidosis (DKA) at admission was more frequently associated with cognitive deterioration, in comparison with hypoglycemic events (p=0.03).In T2DM, cognitive decline (p=0.006, r=-0.342) was associated with the presence of anemia.In T2DM women, treatment with calcium-channel blockers facilitated cognitive decrement (p=0.01, r=-0.339), whereas in men, therapy for distal symmetric polyneuropathy resulted in higher MMSE/MoCA test scores (p=0.00, r=0.72).In T1DM, a higher glycemic burden evidenced by increased HbA1c (p=0.03, r=-0.364) and glycemia at admission (p=0.01, r=-0.389) was suggestive to a more severe form of cognitive impairment. Distal symmetrical polyneuropathy (p=0.05, r=-0.305) and diabetic retinopathy (p=0.03, r=-0.102) was often co-occurring with cognitive decline.Cognitive deterioration was associated with insulin therapy (p=0.05, r=-0.232).

Conclusion: The prevalence of cognitive decline is high in the diabetic population. Risk stratification must start at diagnosis and physicians should follow disease progression periodically, with special attention attributed to T1DM and the middle-aged population.

References

Liu M, Wang J, Zeng J, He Y . Relationship between serum uric acid level and mild cognitive impairment in Chinese community elderly. BMC Neurol. 2017; 17(1):146. PMC: 5539640. DOI: 10.1186/s12883-017-0929-8. View

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

Lacy M, Moran C, Gilsanz P, Beeri M, Karter A, Whitmer R . Comparison of cognitive function in older adults with type 1 diabetes, type 2 diabetes, and no diabetes: results from the Study of Longevity in Diabetes (SOLID). BMJ Open Diabetes Res Care. 2022; 10(2). PMC: 8961108. DOI: 10.1136/bmjdrc-2021-002557. View

Burkauskas J, Noreikaite A, Bunevicius A, Brozaitiene J, Neverauskas J, Mickuviene N . Beta-1-Selective Beta-Blockers and Cognitive Functions in Patients With Coronary Artery Disease: A Cross-Sectional Study. J Neuropsychiatry Clin Neurosci. 2015; 28(2):143-6. DOI: 10.1176/appi.neuropsych.15040088. View

Munshi M . Cognitive Dysfunction in Older Adults With Diabetes: What a Clinician Needs to Know. Diabetes Care. 2017; 40(4):461-467. DOI: 10.2337/dc16-1229. View

Maxwell C, Hogan D, Ebly E . Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ. 1999; 161(5):501-6. PMC: 1230578. View

Tomic D, Shaw J, Magliano D . The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022; 18(9):525-539. PMC: 9169030. DOI: 10.1038/s41574-022-00690-7. View

Brown E, Heerspink H, Cuthbertson D, Wilding J . SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021; 398(10296):262-276. DOI: 10.1016/S0140-6736(21)00536-5. View

Rocca W, Mielke M, Vemuri P, Miller V . Sex and gender differences in the causes of dementia: a narrative review. Maturitas. 2014; 79(2):196-201. PMC: 4169309. DOI: 10.1016/j.maturitas.2014.05.008. View

10.

Kawamura T, Umemura T . Is cognitive impairment the fourth diabetic microvascular complication?. J Diabetes Investig. 2014; 2(5):351-3. PMC: 4019300. DOI: 10.1111/j.2040-1124.2011.00140.x. View

11.

Jia X, Wang Z, Huang F, Su C, Du W, Jiang H . A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study. BMC Psychiatry. 2021; 21(1):485. PMC: 8489046. DOI: 10.1186/s12888-021-03495-6. View

12.

Strachan M, Deary I, EWING F, Frier B . Recovery of cognitive function and mood after severe hypoglycemia in adults with insulin-treated diabetes. Diabetes Care. 2000; 23(3):305-12. DOI: 10.2337/diacare.23.3.305. View

13.

Cansino S, Hernandez-Ramos E, Estrada-Manilla C, Torres-Trejo F, Martinez-Galindo J, Ayala-Hernandez M . The decline of verbal and visuospatial working memory across the adult life span. Age (Dordr). 2013; 35(6):2283-302. PMC: 3825012. DOI: 10.1007/s11357-013-9531-1. View

14.

Ganguli M, Beer J, Zmuda J, Ryan C, Sullivan K, Chang C . Aging, Diabetes, Obesity, and Cognitive Decline: A Population-Based Study. J Am Geriatr Soc. 2020; 68(5):991-998. PMC: 8597580. DOI: 10.1111/jgs.16321. View

15.

Choi J, Kim T, Han E . Anemia and incidence of dementia in patients with new-onset type 2 diabetes: a nationwide population-based cohort study. BMJ Open Diabetes Res Care. 2020; 8(1). PMC: 7398094. DOI: 10.1136/bmjdrc-2020-001289. View

16.

Nunley K, Rosano C, Ryan C, Jennings J, Aizenstein H, Zgibor J . Clinically Relevant Cognitive Impairment in Middle-Aged Adults With Childhood-Onset Type 1 Diabetes. Diabetes Care. 2015; 38(9):1768-76. PMC: 4542271. DOI: 10.2337/dc15-0041. View

17.

Malik A, Ahmed M, Mansoor S, Ambreen S, Usman B, Shehryar M . Cognitive Impairment in Type 2 Diabetes Mellitus. Cureus. 2022; 14(2):e22193. PMC: 8925983. DOI: 10.7759/cureus.22193. View

18.

Biessels G, Despa F . Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018; 14(10):591-604. PMC: 6397437. DOI: 10.1038/s41574-018-0048-7. View

19.

Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri C . The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013; 9(1):63-75.e2. DOI: 10.1016/j.jalz.2012.11.007. View

20.

Ng T, Feng L, Yap K, Lee T, Tan C, Winblad B . Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis. 2014; 41(1):61-8. DOI: 10.3233/JAD-131901. View